Vireo Growth (VREOF) Total Non-Current Liabilities (2021 - 2026)
Vireo Growth (VREOF) posted Total Non-Current Liabilities of $604.7 million for Q1 2026, up 19.08% sequentially from $507.8 million in Q4 2025, and up 166.89% YoY from $226.6 million in Q1 2025.
Vireo Growth (VREOF) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Vireo Growth has reported Total Non-Current Liabilities for 6 years, with the latest figure at $604.7 million in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 166.89% year-over-year to $604.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $604.7 million (up 166.89% YoY) and the FY2025 annual result came in at $507.8 million, up 127.41% from the prior year.
- Total Non-Current Liabilities rose to $604.7 million in Q1 2026 per VREOF's latest filing, from $507.8 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $604.7 million in Q1 2026 and troughed at $155.7 million in Q4 2022.
- A 5-year average of $286.3 million and a median of $217.0 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities climbed 6.14% in 2025, then jumped 166.89% in 2026.
- Over 5 years, Total Non-Current Liabilities stood at $155.7 million in 2022, then grew by 27.92% to $199.2 million in 2023, then rose by 12.11% to $223.3 million in 2024, then surged by 127.41% to $507.8 million in 2025, then rose by 19.08% to $604.7 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $604.7 million, $507.8 million, and $431.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 334.00 Mn |
| 10 | Vireo Growth | 487.39 Mn | 345.09 Mn | 95.30 Mn | 830.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 604.70 Mn |
| Dec 31, 2025 | 507.80 Mn |
| Sep 30, 2025 | 431.51 Mn |
| Jun 30, 2025 | 380.13 Mn |
| Mar 31, 2025 | 226.57 Mn |
| Dec 31, 2024 | 223.30 Mn |
| Sep 30, 2024 | 204.66 Mn |
| Jun 30, 2024 | 217.04 Mn |
| Mar 31, 2024 | 213.46 Mn |
| Dec 31, 2023 | 199.19 Mn |
| Sep 30, 2023 | 184.29 Mn |
| Jun 30, 2023 | 173.66 Mn |
| Dec 31, 2022 | 155.71 Mn |
| Sep 30, 2021 | 110.17 Mn |
| Jun 30, 2021 | 52.73 Mn |
| Mar 31, 2021 | 58.01 Mn |